Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance.

White-Koning M, Paludetto MN, Le Louedec F, Gladieff L, Chevreau C, Chatelut E, Puisset F.

Cancer Chemother Pharmacol. 2020 Jan 9. doi: 10.1007/s00280-019-04020-z. [Epub ahead of print]

PMID:
31915969
2.

Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology.

Chatelut E, Le Louedec F, Milano G.

Clin Pharmacokinet. 2019 Nov 7. doi: 10.1007/s40262-019-00837-2. [Epub ahead of print] Review.

PMID:
31701469
3.

Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions in Vitro and in Patient Samples.

Paludetto MN, Stigliani JL, Robert A, Bernardes-Génisson V, Chatelut E, Puisset F, Arellano C.

Chem Res Toxicol. 2020 Jan 21;33(1):181-190. doi: 10.1021/acs.chemrestox.9b00205. Epub 2019 Sep 26.

PMID:
31535851
4.

A fast UPLC-HILIC method for an accurate quantification of dendrogenin A in human tissues.

Soulès R, Audouard-Combe F, Huc-Claustre E, de Medina P, Rives A, Chatelut E, Dalenc F, Franchet C, Silvente-Poirot S, Poirot M, Allal B.

J Steroid Biochem Mol Biol. 2019 Nov;194:105447. doi: 10.1016/j.jsbmb.2019.105447. Epub 2019 Aug 12.

PMID:
31415823
5.

Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug-drug interactions and hepatotoxicity.

Paludetto MN, Puisset F, Chatelut E, Arellano C.

Med Res Rev. 2019 Nov;39(6):2105-2152. doi: 10.1002/med.21577. Epub 2019 May 20. Review.

PMID:
31111528
6.

Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities.

Veal GJ, Amankwatia EB, Paludetto MN, Möcklinghoff T, Thomson F, André N, Ciccolini J, Chatelut E.

Ther Drug Monit. 2019 Apr;41(2):142-159. doi: 10.1097/FTD.0000000000000606. Review.

PMID:
30883508
7.

Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.

Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, Guigay J, Cupissol D, Delord JP, Lallemant B, Alfonsi M, Aubry K, Mazel M, Becher F, Perriard F, Chatelut E, Thomas F.

Br J Clin Pharmacol. 2019 Jun;85(6):1357-1366. doi: 10.1111/bcp.13907. Epub 2019 Apr 13.

PMID:
30811063
8.

Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.

Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer JC, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet-Bach I, Filleron T, Roché H, Chatelut E, White-Koning M, Thomas F.

Clin Pharmacol Ther. 2019 Sep;106(3):585-595. doi: 10.1002/cpt.1404. Epub 2019 Apr 10.

PMID:
30786012
9.

Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study.

Jouinot A, Royer B, Chatelut E, Moeung S, Assié G, Thomas-Schoemann A, Bertherat J, Goldwasser F, Blanchet B.

Endocr Connect. 2018 Dec 1;7(12):1409-1414. doi: 10.1530/EC-18-0428.

10.

How can we best monitor 5-FU administration to maximize benefit to risk ratio?

Goirand F, Lemaitre F, Launay M, Tron C, Chatelut E, Boyer JC, Bardou M, Schmitt A.

Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1303-1313. doi: 10.1080/17425255.2018.1550484. Epub 2018 Nov 23. Review.

11.

Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.

Moeung S, Chevreau C, Poinsignon V, Guitton J, Lelièvre B, Ciccolini J, Gladieff L, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Delahousse J, Filleron T, Lochon I, Chatelut E, Thomas F.

Ther Drug Monit. 2019 Feb;41(1):66-74. doi: 10.1097/FTD.0000000000000569.

PMID:
30299429
12.

[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].

Lemaitre F, Goirand F, Launay M, Chatelut E, Boyer JC, Evrard A, Paludetto MN, Guilhaumou R, Ciccolini J, Schmitt A.

Bull Cancer. 2018 Sep;105(9):790-803. doi: 10.1016/j.bulcan.2018.06.008. Epub 2018 Aug 10. Review. French.

13.

Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.

Puszkiel A, Noé G, Bellesoeur A, Kramkimel N, Paludetto MN, Thomas-Schoemann A, Vidal M, Goldwasser F, Chatelut E, Blanchet B.

Clin Pharmacokinet. 2019 Apr;58(4):451-467. doi: 10.1007/s40262-018-0703-0. Review.

PMID:
30094711
14.

Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.

Beauvais D, Goossens JF, Boyle E, Allal B, Lafont T, Chatelut E, Herbaux C, Morschhauser F, Genay S, Odou P, Danel C.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Sep 1;1093-1094:158-166. doi: 10.1016/j.jchromb.2018.06.026. Epub 2018 Jun 15.

15.

Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali.

Oumar AA, Bagayoko-Maiga K, Bahachimi A, Maiga M, Cere MC, Diarra Z, Chatelut E, Sylla M, Murphy RL, Dao S, Gandia P.

J Pharmacol Exp Ther. 2018 Sep;366(3):479-484. doi: 10.1124/jpet.118.249938. Epub 2018 Jul 9.

PMID:
29986950
16.

Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.

Thomas F, Veal GJ, El Balkhi S, Lafont T, Picard N, Brugières L, Chatelut E, Piguet C.

Cancer Chemother Pharmacol. 2018 Aug;82(2):361-365. doi: 10.1007/s00280-018-3625-5. Epub 2018 Jun 19.

PMID:
29922990
17.

Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Puszkiel A, Bauriaud-Mallet M, Bourgeois R, Dierickx L, Courbon F, Chatelut E.

Clin Pharmacokinet. 2019 Feb;58(2):213-222. doi: 10.1007/s40262-018-0674-1.

PMID:
29736841
18.

Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS.

Paludetto MN, Puisset F, Le Louedec F, Allal B, Lafont T, Chatelut E, Arellano C.

J Pharm Biomed Anal. 2018 May 30;154:373-383. doi: 10.1016/j.jpba.2018.03.013. Epub 2018 Mar 9.

PMID:
29571135
19.

Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.

White-Koning M, Osborne C, Paci A, Boddy AV, Chatelut E, Veal GJ.

Eur J Cancer. 2018 Mar;91:56-67. doi: 10.1016/j.ejca.2017.11.029. Epub 2018 Jan 12.

20.

Determination of dolutegravir's unbound fraction in human plasma using validated equilibrium dialysis and LC-MS/MS methods.

Metsu D, Lanot T, Fraissinet F, Picot M, Concordet D, Cabrol M, Dubois-Galopin F, Chatelut E, Delobel P, Gandia P.

Clin Chim Acta. 2018 Apr;479:56-65. doi: 10.1016/j.cca.2017.12.034. Epub 2017 Dec 22.

PMID:
29277535
21.

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

Massabeau C, Khalifa J, Filleron T, Modesto A, Bigay-Gamé L, Plat G, Dierickx L, Aziza R, Rouquette I, Gomez-Roca C, Mounier M, Delord JP, Toulas C, Olivier P, Chatelut E, Mazières J, Cohen-Jonathan Moyal E.

Clin Lung Cancer. 2018 May;19(3):e277-e285. doi: 10.1016/j.cllc.2017.11.002. Epub 2017 Nov 21.

PMID:
29221762
22.

Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.

Chatelut E, Bruno R, Ratain MJ.

Clin Pharmacol Ther. 2018 Jun;103(6):956-958. doi: 10.1002/cpt.937. Epub 2017 Dec 1.

PMID:
29194586
23.

Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.

Moeung S, Chevreau C, Broutin S, Guitton J, Lelièvre B, Ciccolini J, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Paci A, Marsili S, Malard L, Chatelut E, Thomas F.

Clin Cancer Res. 2017 Dec 1;23(23):7171-7179. doi: 10.1158/1078-0432.CCR-17-1344. Epub 2017 Sep 19.

24.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.

Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J.

Semin Oncol. 2017 Apr;44(2):159-160. doi: 10.1053/j.seminoncol.2017.06.001. Epub 2017 Jul 4. No abstract available.

PMID:
28923215
25.

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.

Négrier S, Pérol D, Bahleda R, Hollebecque A, Chatelut E, Boyle H, Cassier P, Metzger S, Blanc E, Soria JC, Escudier B.

BMC Cancer. 2017 Aug 15;17(1):547. doi: 10.1186/s12885-017-3527-7.

26.

Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?

Metsu D, Toutain PL, Chatelut E, Delobel P, Gandia P.

J Antimicrob Chemother. 2017 Sep 1;72(9):2407-2409. doi: 10.1093/jac/dkx176.

PMID:
28595364
27.

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G.

PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017.

28.

Population Pharmacokinetic Approach Applied to Positron Emission Tomography: Computed Tomography for Tumor Tissue Identification in Patients with Glioma.

Gandia P, Jaudet C, Everaert H, Heemskerk J, Vanbinst AM, de Mey J, Duerinck J, Neyns B, de Ridder M, Chatelut E, Concordet D.

Clin Pharmacokinet. 2017 Aug;56(8):953-961. doi: 10.1007/s40262-016-0490-4.

PMID:
27995528
29.

Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?

Metsu D, Seraissol P, Delobel P, Cinq-Frais C, Cuzin L, Izopet J, Chatelut E, Gandia P.

Fundam Clin Pharmacol. 2017 Apr;31(2):245-253. doi: 10.1111/fcp.12245. Epub 2016 Oct 25.

PMID:
27664801
30.

Population Pharmacokinetics of Tracers: A New Tool for Medical Imaging?

Gandia P, Jaudet C, Chatelut E, Concordet D.

Clin Pharmacokinet. 2017 Feb;56(2):101-106. doi: 10.1007/s40262-016-0437-9.

PMID:
27395047
31.

Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.

Lévi F, Karaboué A, Etienne-Grimaldi MC, Paintaud G, Focan C, Innominato P, Bouchahda M, Milano G, Chatelut E.

Clin Pharmacokinet. 2017 Feb;56(2):165-177. doi: 10.1007/s40262-016-0431-2.

PMID:
27393140
32.

Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.

Puszkiel A, White-Koning M, Dupin N, Kramkimel N, Thomas-Schoemann A, Noé G, Chapuis N, Vidal M, Goldwasser F, Chatelut E, Blanchet B.

Pharmacol Res. 2016 Nov;113(Pt A):709-718. doi: 10.1016/j.phrs.2016.06.032. Epub 2016 Jul 1.

PMID:
27378568
33.

Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.

Dalenc F, Iuliano L, Filleron T, Zerbinati C, Voisin M, Arellano C, Chatelut E, Marquet P, Samadi M, Roché H, Poirot M, Silvente-Poirot S.

J Steroid Biochem Mol Biol. 2017 May;169:210-218. doi: 10.1016/j.jsbmb.2016.06.010. Epub 2016 Jun 22.

PMID:
27343991
34.

Quinine unbound concentration is the best marker for therapeutic drug monitoring.

de Pablos-Martinez C, Porte L, Fraissinet F, Berry A, Séraissol P, Lavit M, Chatelut E, Concordet D, Gandia P.

Therapie. 2016 Oct;71(5):487-489. doi: 10.1016/j.therap.2016.02.032. Epub 2016 Apr 11.

PMID:
27203159
35.

Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.

Sauzay C, White-Koning M, Hennebelle I, Deluche T, Delmas C, Imbs DC, Chatelut E, Thomas F.

Pharmacol Res. 2016 Aug;110:89-95. doi: 10.1016/j.phrs.2016.05.012. Epub 2016 May 10.

PMID:
27178732
36.

Quinine Unbound Concentration Has to Be Used for Therapeutic Drug Monitoring.

de Pablos-Martinez C, Porte L, Fraissinet F, Berry A, Séraissol P, Lavit M, Chatelut E, Concordet D, Gandia P.

Ther Drug Monit. 2016 Aug;38(4):556-7. doi: 10.1097/FTD.0000000000000304. No abstract available.

PMID:
27019100
37.

Pharmacokinetic interaction between pazopanib and cisplatin regimen.

Imbs DC, Diéras V, Bachelot T, Campone M, Isambert N, Joly F, Jimenez M, Lafont T, Chatelut E.

Cancer Chemother Pharmacol. 2016 Feb;77(2):385-92. doi: 10.1007/s00280-015-2953-y. Epub 2016 Jan 16.

PMID:
26779916
38.

High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).

Phelip JM, Mineur L, De la Fouchardière C, Chatelut E, Quesada JL, Roblin X, Pezet D, Mendoza C, Buc E, Rivoire M.

Ann Surg Oncol. 2016 Jul;23(7):2161-6. doi: 10.1245/s10434-015-5072-4. Epub 2016 Jan 6.

PMID:
26739304
39.

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.

Diéras V, Bachelot T, Campone M, Isambert N, Joly F, Le Tourneau C, Cassier P, Bompas E, Fumoleau P, Noal S, Orsini C, Jimenez M, Imbs DC, Chatelut E.

Oncol Ther. 2016;4(2):211-223. doi: 10.1007/s40487-016-0027-x. Epub 2016 Aug 18.

40.

Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.

Imbs DC, Paludetto MN, Négrier S, Powell H, Lafont T, White-Koning M, Chatelut E, Thomas F.

Invest New Drugs. 2016 Feb;34(1):41-8. doi: 10.1007/s10637-015-0304-9. Epub 2015 Nov 16.

PMID:
26572909
41.

Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.

Mbatchi LC, Schmitt A, Thomas F, Cazaubon Y, Robert J, Lumbroso S, Brouillet JP, Pourquier P, Chatelut E, Boyer JC, Evrard A.

Pharmacogenomics. 2015;16(13):1439-50. doi: 10.2217/pgs.15.84. Epub 2015 Aug 12.

PMID:
26267044
42.

Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.

Thomas F, Hennebelle I, Delmas C, Lochon I, Dhelens C, Garnier Tixidre C, Bonadona A, Penel N, Goncalves A, Delord JP, Toulas C, Chatelut E.

Clin Pharmacol Ther. 2016 Feb;99(2):235-42. doi: 10.1002/cpt.210. Epub 2015 Nov 10.

PMID:
26265035
43.

Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science?

Marquet P, Longeray PH, Barlesi F; participants of round table N°1 of Giens XXX:, Ameye V, Augé P, Cazeneuve B, Chatelut E, Diaz I, Diviné M, Froguel P, Goni S, Gueyffier F, Hoog-Labouret N, Mourah S, Morin-Surroca M, Perche O, Perin-Dureau F, Pigeon M, Tisseau A, Verstuyft C.

Therapie. 2015 Jan-Feb;70(1):1-19. doi: 10.2515/therapie/2014231. Epub 2015 Feb 16. English, French.

PMID:
25679189
44.

Recherche translationnelle : médecine personnalisée, médecine de précision, thérapies ciblées : marketing ou science ?

Marquet P, Longeray PH, Barlesi F; les participants à la table ronde N°1 de Giens XXX :, Ameye V, Augé P, Cazeneuve B, Chatelut E, Diaz I, Diviné M, Froguel P, Goni S, Gueyffier F, Hoog-Labouret N, Mourah S, Morin-Surroca M, Perche O, Perin-Dureau F, Pigeon M, Tisseau A, Verstuyft C.

Therapie. 2015 Jan-Feb;70(1):1-10. doi: 10.2515/therapie/2014230. French. No abstract available.

PMID:
27393393
45.

Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment.

Pastor ML, Laffont CM, Gladieff L, Chatelut E, Concordet D.

Pharm Res. 2015 Feb;32(2):654-64. doi: 10.1007/s11095-014-1493-1. Epub 2014 Sep 4.

PMID:
25186439
46.

An UPLC-MS/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers.

Arellano C, Allal B, Goubaa A, Roché H, Chatelut E.

J Pharm Biomed Anal. 2014 Nov;100:254-261. doi: 10.1016/j.jpba.2014.07.033. Epub 2014 Aug 4.

PMID:
25173109
47.
48.

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.

Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, Veal G, Astier A.

Eur J Cancer. 2014 Aug;50(12):2020-36. doi: 10.1016/j.ejca.2014.04.015. Epub 2014 Jun 10. Review.

PMID:
24928190
49.

Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.

Paci A, Veal G, Bardin C, Levêque D, Widmer N, Beijnen J, Astier A, Chatelut E.

Eur J Cancer. 2014 Aug;50(12):2010-9. doi: 10.1016/j.ejca.2014.04.014. Epub 2014 Jun 2. Review.

PMID:
24889915
50.

Therapeutic drug monitoring in cancer--are we missing a trick?

Bardin C, Veal G, Paci A, Chatelut E, Astier A, Levêque D, Widmer N, Beijnen J.

Eur J Cancer. 2014 Aug;50(12):2005-9. doi: 10.1016/j.ejca.2014.04.013. Epub 2014 May 27.

PMID:
24878063

Supplemental Content

Loading ...
Support Center